← Back to home

Novartis' Kisqali Cuts Risk of Death by 19% in High-Risk Early Breast Cancer, Trial Shows

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Novartis' Kisqali lowered the risk of death by 19.1% after six…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home